Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amikacin versus ertapenem for ceftriaxone-resistant urosepsis with secondary bacteremia
MOH_2022-09-05_012028Phase 4Not yet recruiting
- Sponsor
- ד"ר יסמין מאור
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in urosepsis, urinary tract infection (UTI) and Bacteremia comparing Intravenous amikacin with Intravenous ertapenem (2 arms). Planned start May 2022; status: not yet recruiting.
02
Drugs
amikacinertapenem
03
Conditions
urosepsisurinary tract infection (UTI)Bacteremia
Beyond the preview
Go deeper on MOH_2022-09-05_012028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-09-05_012028.